These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 22312548)

  • 1. Optimizing Liposomal Cisplatin Efficacy through Membrane Composition Manipulations.
    Zisman N; Dos Santos N; Johnstone S; Tsang A; Bermudes D; Mayer L; Tardi P
    Chemother Res Pract; 2011; 2011():213848. PubMed ID: 22312548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Study of Liposomal Formulations to Improve the Delivery of Aquated Cisplatin to a Multidrug Resistant Tumor.
    Zhao Y; May JP; Chen IW; Undzys E; Li SD
    Pharm Res; 2015 Oct; 32(10):3261-8. PubMed ID: 25964047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib.
    Korani M; Nikoofal-Sahlabadi S; Nikpoor AR; Ghaffari S; Attar H; Mashreghi M; Jaafari MR
    Anticancer Agents Med Chem; 2020; 20(6):700-708. PubMed ID: 31893998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations.
    Johnston MJ; Semple SC; Klimuk SK; Edwards K; Eisenhardt ML; Leng EC; Karlsson G; Yanko D; Cullis PR
    Biochim Biophys Acta; 2006 Jan; 1758(1):55-64. PubMed ID: 16487476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models.
    Webb MS; Harasym TO; Masin D; Bally MB; Mayer LD
    Br J Cancer; 1995 Oct; 72(4):896-904. PubMed ID: 7547237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A simple passive equilibration method for loading carboplatin into pre-formed liposomes incubated with ethanol as a temperature dependent permeability enhancer.
    Wehbe M; Malhotra A; Anantha M; Roosendaal J; Leung AWY; Plackett D; Edwards K; Gilabert-Oriol R; Bally MB
    J Control Release; 2017 Apr; 252():50-61. PubMed ID: 28286316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Encapsulation, controlled release, and antitumor efficacy of cisplatin delivered in liposomes composed of sterol-modified phospholipids.
    Kieler-Ferguson HM; Chan D; Sockolosky J; Finney L; Maxey E; Vogt S; Szoka FC
    Eur J Pharm Sci; 2017 May; 103():85-93. PubMed ID: 28263913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of phospholipid on the physicochemical properties and anti-tumor efficacy of liposomes encapsulating cisplatin in mice bearing C26 colon carcinoma.
    Alavizadeh SH; Badiee A; Golmohammadzadeh S; Jaafari MR
    Int J Pharm; 2014 Oct; 473(1-2):326-33. PubMed ID: 25051111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved pharmacokinetics and reduced toxicity of brucine after encapsulation into stealth liposomes: role of phosphatidylcholine.
    Chen J; Yan GJ; Hu RR; Gu QW; Chen ML; Gu W; Chen ZP; Cai BC
    Int J Nanomedicine; 2012; 7():3567-77. PubMed ID: 22904620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
    Charrois GJ; Allen TM
    Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stable and sustained release liposomal formulations of celecoxib: In vitro and in vivo anti-tumor evaluation.
    Matbou Riahi M; Sahebkar A; Sadri K; Nikoofal-Sahlabadi S; Jaafari MR
    Int J Pharm; 2018 Apr; 540(1-2):89-97. PubMed ID: 29371019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
    Meerum Terwogt JM; Groenewegen G; Pluim D; Maliepaard M; Tibben MM; Huisman A; ten Bokkel Huinink WW; Schot M; Welbank H; Voest EE; Beijnen JH; Schellens JM
    Cancer Chemother Pharmacol; 2002 Mar; 49(3):201-10. PubMed ID: 11935212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peritoneal retention of liposomes: Effects of lipid composition, PEG coating and liposome charge.
    Dadashzadeh S; Mirahmadi N; Babaei MH; Vali AM
    J Control Release; 2010 Dec; 148(2):177-86. PubMed ID: 20800629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors.
    Lim HJ; Masin D; McIntosh NL; Madden TD; Bally MB
    J Pharmacol Exp Ther; 2000 Jan; 292(1):337-45. PubMed ID: 10604968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors.
    Mayer LD; Bally MB; Loughrey H; Masin D; Cullis PR
    Cancer Res; 1990 Feb; 50(3):575-9. PubMed ID: 2297698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibacterial efficacy against an in vivo Salmonella typhimurium infection model and pharmacokinetics of a liposomal ciprofloxacin formulation.
    Webb MS; Boman NL; Wiseman DJ; Saxon D; Sutton K; Wong KF; Logan P; Hope MJ
    Antimicrob Agents Chemother; 1998 Jan; 42(1):45-52. PubMed ID: 9449259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A study on the role of cholesterol and phosphatidylcholine in various features of liposomal doxorubicin: From liposomal preparation to therapy.
    Farzaneh H; Ebrahimi Nik M; Mashreghi M; Saberi Z; Jaafari MR; Teymouri M
    Int J Pharm; 2018 Nov; 551(1-2):300-308. PubMed ID: 30243944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity.
    Hong RL; Tseng YL
    Cancer; 2001 May; 91(9):1826-33. PubMed ID: 11335910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of a passive equilibration methodology to encapsulate cisplatin into preformed thermosensitive liposomes.
    Woo J; Chiu GN; Karlsson G; Wasan E; Ickenstein L; Edwards K; Bally MB
    Int J Pharm; 2008 Feb; 349(1-2):38-46. PubMed ID: 17728083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates.
    Allen TM; Mumbengegwi DR; Charrois GJ
    Clin Cancer Res; 2005 May; 11(9):3567-73. PubMed ID: 15867261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.